We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Horizon Discovery and University of Torino Receive Eurostars Award

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Horizon Discovery and University of Torino Receive Eurostars Award"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Horizon Discovery (Horizon) and the University of Torino, Department of Oncological Sciences, announced that they have been awarded a three-year Eurostars grant under the EUREKA and EU Seventh Framework Programme for Research and Technological Development.

The grant application entitled “Interrogation of Somatic and Inherited Gene-variations for Human Therapy (INSIGHT)” was ranked first amongst all applications received in the UK and Italy, and third across the entire EU.

The ‘INSIGHT’ program will explore a novel class of inherited and somatic non-coding mutations associated with cancer causation. Once their biological role and mechanisms in cancer have been confirmed or elucidated, these disease models will be made available to the wider research community and profiled (by Horizon) for all known existing cancer drugs that may target these cancer genetic variations, to discover potential new therapeutic options for patients.

Horizon will perform the in vitro gene engineering and drug screening; and Professor Alberto Bardelli will identify other cancer associated SNPs for modeling.

Professor Bardelli is a leader in the field of cancer genetics and therapy and his work is actively leading to the adoption of new and more effective ‘Personalized Medicine’ strategies by pharmaceutical companies and healthcare agencies; in particular his landmark research recently linking mutant K-Ras and other genetic mutations to resistance to novel EGFR-targeted therapies in colon cancer.

The grant which begins in March 2010 is spread over a period of three years and will contribute toward a $1,000,000 program of work that will lead to the marketing by Horizon of a panel of new patient relevant X-MAN™ disease models and the co-ownership of new inventions that will be commercialized via Horizon.